Posted by Michael Wonder on 10 Jun 2021
Astellas’ Xtandi bags NICE approval in prostate cancer
10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate cancer.
The positive decision is supported by data from the Phase 3 ARCHES trial, which showed Xtandi (enzalutamide) plus standard androgen deprivation therapy reduced the risk of metastatic progression or death by 61% compared to placebo plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
